** Shares of AcelRx Pharmaceuticals fall 10.5% to 62 cents

** Co said on Friday the U.S health regulator had declined to issue Emergency Use Authorization $(EUA.UK)$ for Niyad, a device used to deliver co's blood thinner nafamostat

** The FDA said review of co's EUA not a priority due to volume of EUA requests

** Co said it expects to submit a premarket application for Niyad to the FDA in 2024

** Including session moves, shares down 72.3% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))